Emerging Biologics for Nasal Polyposis Treatment: Market Trends
Nasal polyposis causes benign growths in the nasal mucosa that restrict the nasal airway and are a common ailment. They lower quality of life (QoL), the Nasal Polyps symptoms cause hyposmia or anosmia, and impair sleep in people who are affected. They are a prevalent subset of chronic rhinosinusitis that are frequently linked to persistent nasal inflammation and ailments including asthma (CRS). About 25% of those with chronic rhinosinusitis (CRS) who are also diagnosed with nasal polyps have a disease called chronic rhinosinusitis with nasal polyps (CRSwNP), which can be quite debilitating in adulthood. The Current Nasal Polyposis Treatment Landscape The main goals of modern nasal polyposis treatment are to reduce polyp growth, postpone surgery, or avoid relapse following surgery. Recurrence rates are both high and common. Nasal corticosteroids are typically the first line of treatment for nasal irritation because the cause is typically unclear. Injectable corticosteroids may be used